In 2026, most pharma leaders will still trust a Quality System designed for a world without AI… and that’s exactly how compliance failures happen.
Pharma doesn’t lose approvals because of weak science. It loses them because regulators can’t trust the AI behind it.
90% of pharma data is never used. But the 10% that is… is rewriting who wins and who loses in this industry.
Here’s the uncomfortable truth: validating an AI model once is like approving a drug that reformulates itself overnight. Model risk management is forcing pharma to confront this.
3 years ago, AI was a pilot project in pharma.
Today, it’s everywhere — and risk is scaling faster than governance.
The quiet winner holding it all together? Enterprise Risk Management.
Here’s the uncomfortable truth:
Pharma doesn’t trust most AI vendors.
And without bias controls, audit trails, and transparency, they never will.
Ethical AI is now the price of entry.
